CCR6+ and CXCR3+ cells were less prevalent among cells from control participants compared to those from AAA patients, while the frequency of both CCR4 and CCR5 was higher (and statistically significant for CCR5) in the control participants. This evidence concerns the gene CCR6 and triple-A syndrome.